Clinical trials: Thrombosis; Artery
Thrombosis, Bleeding
Multi-Omics-Based Novel Thrombosis and Bleeding Markers and Risk Model for CHD
Patients with coronary heart disease who take dual antiplatelet therapy face two serious risks: thrombosis and major bleeding. This study aims to develop better ways to predict these risks and guide personalized treatment.
- Conditions
- Thrombosis, Bleeding, Coronary Artery Disease (CAD)
- Trial name
- NCT07523880
- Where
- 3 sites in China
- Volunteers
- 12,154 people
- Sponsor
- Xueyan Zhao
Coronary Artery Disease, Cerebro Vascular Disease
Study the Result of Ayurvedic SUVED & Reimmugen (Colostrum) Treatment on Vascular Disease, CAD, CVA, DVT.
To evaluate the benefits of Ayurvedic SUVED \& REIMMUGEN Colostrum for reduction/reversal of symptoms and study clinical progress in Vascular disease; CAD, CAV, Stroke, DVT patients.
- Conditions
- Coronary Artery Disease, Cerebro Vascular Disease, Ischemic Heart Disease, Deep Vein Thrombosis
- Trial name
- SHARP (NCT02920125)
- Testing
- SUVED, REIMMUGEN
- Where
- India
- Volunteers
- 96 people
- Sponsor
- Sujata Vaidya
Thrombosis; Artery
Impact of Anti-platelet Drug Exposure on Platelet mRNA Splicing in Healthy Subjects
The purpose of this pilot study is to determine how the anti-platelet drug, ticagrelor, impacts platelet mRNA splicing after a single loading dose in 10 healthy participants.
- Trial name
- NCT04088123
- Testing
- Ticagrelor Oral Tablet [Brilinta]
- Where
- 2 sites in United States
- Sponsor
- George Washington University
Healthy
Trial to Assess the Effects of Different Trans-fatty Acids on Endothelial Function in Humans
The aim of the study is to compare a diet rich in trans fatty acids (TFA) from ruminant sources with a diet rich in TFA from hydrogenated vegetable oils (PHVO) in regard to their effects on cardiovascular risk markers…
- Trial name
- NCT00933322
- Testing
- diet enriched with industrial trans fatty acids, diet enriched with ruminant trans fatty acids, diet without any trans fatty acids
- Where
- Switzerland
- Volunteers
- 142 people, healthy volunteers welcome
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Atrial Fibrillation, Valvular Heart Disease
Prolongation of the Interval Between Prothrombin Time Tests in Stable Patients II
More than 2 million patients in North America are treated with warfarin - a "blood thinner" - to prevent blood clots in arteries or veins.
- Conditions
- Atrial Fibrillation, Valvular Heart Disease, Deep Vein Thrombosis, Pulmonary Embolism
- Trial name
- PRINT-II (NCT01654042)
- Testing
- Prolonged interval between PT testing
- Where
- Canada
- Sponsor
- McMaster University
Central Retinal Vein Occlusion
Spontaneous Retinal Artery Pulses (SPARs) as a Prognostic Determinant of Central Retinal Vein Occlusions (CRVO) in Patients With or Without Intravitreal Aflibercept Injections
Central retinal vein occlusion (CRVO) is the second most common retinal vascular disease after diabetic retinopathy. It induces circulatory slowdown and blood stasis, which can appear as retinal hemorrhages.
- Trial name
- PULSOV (NCT04793100)
- Testing
- Ophthalmologic exam at inclusion and 12 months after CRVO, Treatment standardization with aflibercept
- Where
- 3 sites in France
- Volunteers
- 60 people
- Sponsor
- Fondation Ophtalmologique Adolphe de Rothschild